Key facts
- Elisigen’s last known valuation is $74.5M (Jul 2021).
- It has raised $83.7M; the latest was Later Stage VC ($28.8M) in Jan 2026.
- Notable investors include KB Investment, Korea Investment Partners, Korea Development Bank, Partners Investment, Premier Partners — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Elisigen
- ·The full record, as it builds
Funding rounds
No funding rounds for Elisigen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elisigen
Developer of an adeno-associated virus (AAV) gene therapy designed to improve the quality of life of patients. The company utilizes AAV gene therapy applications for treating neurodegenerative disorders and other intractable and rare diseases, enabling patients to reduce their suffering effectively.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 31
- Website
- elisigen.com/
- Ownership
- Privately Held (backing)
Elisigen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elisigen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elisigen in its N-PORT filings yet. We sweep new filings monthly.